Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda ...

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.
Outlook Business on MSNOpinion

Rising inequality, pampered capitalists: Why India must tax its rich

Delhi is the most polluted city in the world. Each winter, its air thickens until it feels like breathing inside a flour mill ...